High-dose chemotherapy for high-risk primary breast cancer: an on-site review of the Bezwoda study

@article{Weiss2000HighdoseCF,
  title={High-dose chemotherapy for high-risk primary breast cancer: an on-site review of the Bezwoda study},
  author={R. Weiss and R. Rifkin and F. M. Stewart and R. Theriault and R. Beveridge},
  journal={The Lancet},
  year={2000},
  volume={355},
  pages={999-1003}
}
  • R. Weiss, R. Rifkin, +2 authors R. Beveridge
  • Published 2000
  • Medicine
  • The Lancet
  • BACKGROUND The efficacy of high-dose chemotherapy with progenitor-cell rescue for women with breast cancer is a controversial issue. Although historically controlled trials have suggested a survival advantage for high-dose chemotherapy, several randomised studies have yet to confirm this advantage. Two studies, however, by Bezwoda, of patients with high-risk and metastatic disease, seemed to show a significant survival advantage for high-dose compared with conventional-dose chemotherapy for… CONTINUE READING
    137 Citations

    Topics from this paper

    Paper Mentions

    Interventional Clinical Trial
    Objectives of the study: This randomized multicenter phase II study compares the tolerability, toxicity and quality of life between two high-dose chemotherapy regimens based on… Expand
    ConditionsHigh-Risk Breast Cancer
    InterventionDrug, Procedure
    High-Dose Chemotherapy in High-Risk Primary Breast Cancer
    • 6
    Is high-dose chemotherapy dead?
    • 6
    Adjuvant chemotherapy for breast cancer: an update.
    • 34
    A critique of the eleven randomised trials of high-dose chemotherapy for breast cancer.
    • K. Antman
    • Medicine
    • European journal of cancer
    • 2001
    • 13
    • Highly Influenced
    An on-site audit of the South African trial of high-dose chemotherapy for metastatic breast cancer and associated publications.
    • R. Weiss, G. Gill, C. Hudis
    • Medicine
    • Journal of clinical oncology : official journal of the American Society of Clinical Oncology
    • 2001
    • 54
    Up-front tandem high-dose chemotherapy compared with standard chemotherapy with doxorubicin and paclitaxel in metastatic breast cancer: results of a randomized trial.
    • 37

    References

    SHOWING 1-10 OF 11 REFERENCES
    Randomized trial of high-dose chemotherapy and blood cell autografts for high-risk primary breast carcinoma.
    • 165
    • PDF
    High-dose chemotherapy with hematopoietic rescue as primary treatment for metastatic breast cancer: a randomized trial.
    • 418
    • PDF
    High-dose combination alkylating agents with bone marrow support as initial treatment for metastatic breast cancer.
    • W. Peters, E. Shpall, +4 authors J. Moore
    • Medicine
    • Journal of clinical oncology : official journal of the American Society of Clinical Oncology
    • 1988
    • 374
    High-dose chemotherapy and autologous bone marrow support as consolidation after standard-dose adjuvant therapy for high-risk primary breast cancer.
    • W. Peters, M. Ross, +7 authors E. Shpall
    • Medicine
    • Journal of clinical oncology : official journal of the American Society of Clinical Oncology
    • 1993
    • 510
    • PDF
    Efficacy, toxicity, and applicability of high-dose sequential chemotherapy as adjuvant treatment in operable breast cancer with 10 or more involved axillary nodes: five-year results.
    • A. Gianni, S. Siena, +11 authors G. Bonadonna
    • Medicine
    • Journal of clinical oncology : official journal of the American Society of Clinical Oncology
    • 1997
    • 185
    High-dose chemotherapy with autologous hematopoietic stem-cell support for breast cancer in North America.
    • 271